• HitIQ signs deal with Western Australian Football Commission
  • Rhthym Bio expands into NZ
  • Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation

HitIQ signs with WAFC

Concussion tech specialist HitIQ (ASX:HIQ) rose 40% this morning after announcing a sales deal with the Western Australian Football Commission (WAFC).

The deal to deploy HitQ concussion management technology will see 180 male and female players from senior and youth competitions fitted with HitIQ’s Nexus Instrumented Mouthguards, and over 600 players registered on the CSX Concussion Assessment application.

Players will wear the Nexus technology for the entirety of the 2023 WAFL season.

HitIQ data is expected to help the WAFC to implement strategies to improve player health and safety in multiple tiers including semi-professional, community, and youth competitions.

The partnership was effectively designed to provide new protocols for surveillance, recording and management of head impacts that can ultimately improve player welfare and performance.

HitIQ says that revenue to be generated under the agreement represents approximately 15% of total operating revenues reported for the year ended 30 June.

Rhythym Biosciences expands to New Zealand

The cancer diagnostics tech company, Rhythym Biosciences (ASX:RHY), has expended its international regulatory footprint after having successfully registered ColoSTAT with the New Zealand national database of Medical Devices.

This registration will allow the lifesaving cancer detection technology to be marketed and sold across the country.

ColoSTAT is a simple blood test which has the potential to make a material impact on health outcomes through mass screening for higher participation to achieve early diagnosis.

“Bowel cancer is the second highest cause of cancer death in New Zealand, and a growing issue with 1 in 10 now diagnosed under the age of 50,” said Rhythm CEO, Glenn Gilbert.

“We look forward to working with the Ministry of Health’s National Screening Unit to enhance New Zealand’s National Bowel Screening Programme.”


Immutep to present in Boston

Immutep (ASX:IMM) announced that a late-breaking abstract relating to its phase II TACTI-002 trial has been accepted for an oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022.

The oral presentation will include new clinical data for efti, its first-in-class soluble LAG-3 protein, in combination with pembrolizumab in first line non-small cell lung cancer (NSCLC) patients.

The meeting will be held in Boston from 8 to 12 November 2022.

Efti is currently under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and HER2–/HR+ metastatic breast cancer.

Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy.

Efti has previously received Fast Track Designation in first line HNSCC and in first line NSCLC from the US FDA.


Share prices today: